Macular Disease Foundation Australia logo

    Eye Connect offers a new way to support AMD patients.

    PricewaterhouseCoopers (PwC) modelling commissioned in 2019 by MDFA shows 20%[1] of people undergoing treatment for neovascular age-related macular degeneration, or late-stage AMD, cease treatment after their first year.

    To tackle the issue of non-adherence, MDFA is developing the Eye Connect program to provide custom support to people newly diagnosed with late-stage AMD and who are receiving treatment.

    The program is being co-designed with community members who have generously shared their eye injection treatment journey with us through focus groups and surveys.

    The research tells us patients are getting premium care when they see their ophthalmologist for treatment but there is a role for MDFA to support people in between those visits – particularly in the first 12 months.

    We heard many people understand the importance of ongoing treatment to keep their sight but there can be things that get in the way, like transport or cost. 

    Some people are unaware treatment is an ongoing commitment and stop after one injection – which ultimately leads to irretrievable vision loss.

    Eye Connect will equip participants with greater health literacy, promote treatment adherence, and connect them with support and resources to live optimally. This gives people the very best of care in between their visit to their eye specialist.

    More articles like this